Rilzabrutinib Plus Low-Dose Steroid Fails Pemphigus Trial
Rilzabrutinib did not meet primary or secondary endpoints in the phase 3 PEGASUS trial of patients with pemphigus vulgaris or foliaceus.
Source: medscape.com
Dedeef Murrell News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Dedeef Murrell. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Dedeef Murrell Today - Breaking & Trending Today
Sanofi: New Dupixent (dupilumab) analyses reinforce long-term safety and efficacy profile in patients with atopic dermatitis as young as 6 years
Sanofi: New Dupixent (dupilumab) analyses reinforce long-term safety and efficacy profile in patients with atopic dermatitis as young as 6 years as young as 6 years Nearly 30 data presentations at AAD and ESPD across clinical and real-world settings, including the impact of Dupixent on disease measures in uncontrolled moderate-to-severe atopic dermatitis Late-breaking Phase 2 data for rilzabrutinib, an investigational therapy for pemphigus vulgaris, a rare, debilitating autoimmune disease, to be presented at AAD PARIS - April 23, 2021 - New analyses from Dupixent (dupilumab) trials evaluat...
Source: finanznachrichten.de